Matching articles for "Probuphine"

Opioids for Pain

   
The Medical Letter on Drugs and Therapeutics • April 9, 2018;  (Issue 1544)
Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations...
Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Med Lett Drugs Ther. 2018 Apr 9;60(1544):57-64 | Show Full IntroductionHide Full Introduction

Once-Monthly Subcutaneous Buprenorphine (Sublocade) for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • February 26, 2018;  (Issue 1541)
The FDA has approved a subcutaneous (SC) extended-release formulation of the mu-opioid receptor partial agonist and kappa-opioid receptor antagonist buprenorphine (Sublocade – Indivior) for once-monthly...
The FDA has approved a subcutaneous (SC) extended-release formulation of the mu-opioid receptor partial agonist and kappa-opioid receptor antagonist buprenorphine (Sublocade – Indivior) for once-monthly treatment of moderate to severe opioid use disorder. Sublocade is the first injectable buprenorphine product to be approved in the US. Buprenorphine is also available in sublingual formulations with or without the opioid antagonist naloxone, in a buccal formulation with naloxone, and as a subdermal implant (Probuphine).
Med Lett Drugs Ther. 2018 Feb 26;60(1541):35-7 | Show Full IntroductionHide Full Introduction

Drugs for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • June 5, 2017;  (Issue 1522)
Opioid use disorder is a chronic, relapsing disease with both physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of...
Opioid use disorder is a chronic, relapsing disease with both physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the CDC, there were 33,091 deaths related to opioid overdose in the US in 2015, more than in any previous year. Several guidelines on the management of opioid use disorder have recently been published.
Med Lett Drugs Ther. 2017 Jun 5;59(1522):89-96 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder (online only)

   
The Medical Letter on Drugs and Therapeutics • June 5, 2017;  (Issue 1522)
...
View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder
Med Lett Drugs Ther. 2017 Jun 5;59(1522):e96-7 | Show Full IntroductionHide Full Introduction

Buprenorphine Implants (Probuphine) for Opioid Dependence

   
The Medical Letter on Drugs and Therapeutics • July 18, 2016;  (Issue 1499)
The FDA has approved subdermal implants of the partial opioid agonist buprenorphine (Probuphine – Titan) for maintenance treatment of opioid dependence in patients stabilized on low to moderate doses of...
The FDA has approved subdermal implants of the partial opioid agonist buprenorphine (Probuphine – Titan) for maintenance treatment of opioid dependence in patients stabilized on low to moderate doses of transmucosal buprenorphine. Probuphine was designed to provide continuous low levels of buprenorphine for 6 months and to safeguard against illicit use of the drug.
Med Lett Drugs Ther. 2016 Jul 18;58(1499):94-5 | Show Full IntroductionHide Full Introduction